You are here

Article Text

Article menu
Download PDFPDF
Repeat warning on ▾ valproate in pregnancy as message fails to raise awareness

https://doi.org/10.1136/dtb.2017.7.0497

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Repeat warning on ▾ valproate in pregnancy as message fails to raise awareness

    The Medicines and Healthcare products Regulatory Agency (MHRA) has issued the latest in a series of alerts on the risks of developmental disorders and birth defects associated with use of valproate-containing medicines during pregnancy.1 In 2015, the MHRA highlighted data that showed that babies born to mothers who take medicines related to valproate during pregnancy have a 30-40% risk of developmental disability and a 10% risk of birth defects.2 Despite communications to prescribers in January 2015 and February 2016 on the …

    View Full Text